SAR402663

PreclinicalBiologic

SAR402663 is one of 5 biologic programs targeting Neovascular Age-related Macular Degeneration. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neovascular Age-Related Macular DegenerationActive, not recruiting

Neovascular Age-Related Macular DegenerationPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Neovascular Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

4 2

Eylea

Regeneron

Phase 3

2 3

Lucentis

Novartis

Phase 3

1 4

Diluent

Sanofi

Preclinical

1 5

SAR402663

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

PreclinicalActive, not recruiting

Neovascular Age-Related Macular Degeneration

NCT06660667

Clinical

Trials by Indication[1]

Neovascular Age-related Macular Degeneration1 trial

A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration

Active, not recruiting· Sanofi logo

Sanofi·Preclinical·NCT06660667·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAR402663. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR402663 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR402663. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Sanofi

SAR402663

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Neovascular Age-related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News